Learn how Dupixent helps diverse eczema patients and why inclusive clinical trials are vital for fair healthcare.

Rezpegaldesleukin, an investigational interleukin-pathway agonist, demonstrated efficacy and safety for people with moderate ...

The Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid.

Nektar, which accused Lilly of making errors in its analysis of the data, forged ahead with the programme and started the ...

Adults on dupilumab for severe chronic rhinosinusitis with nasal polyps had better outcomes than those who used omalizumab, ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

Eli Lilly’s tirzepatide is expected to be worth $62 billion annually by 2030, according to Evaluate. That valuation would be ...

Regeneron's Dupixent leads growth as Eylea sales decline and valuation is attractive, but growth is delayed by 2-3 years.

The US Food and Drug Administration (FDA) has approved Sanofi and Regeneron’s Dupixent (dupilumab) as a treatment option for ...

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid.

NKTR stock is up around 150% in today’s trading session following the recently announced positive results from its Phase 2b ...

Rezpegaldesleukin, an IL-pathway agonist and regulatory T-cell (Treg) proliferator, was being investigated in the REZOLVE-AD ...